Request for Letters Rogatory Denied Due to Tardiness and Likely Delay to Trial Date

Dec 4, 2019

Reading Time : 2 min

The case began on July 19, 2018, when Luminati Networks Ltd. filed a complaint for patent infringement against UAB Tesonet (“Tesonet”). In its initial disclosures, Tesonet disclosed two witnesses who were on the board of directors of Luminati and also managing partners of EMK Capital, a non-party UK-based private equity fund that is an investor in Luminati.

The court issued a scheduling order setting September 16, 2019, as the close of fact discovery. On September 3, 2019, Tesonet and its codefendant filed a motion to compel Luminati to produce documents and emails from EMK. Following an October 1, 2019 hearing, the court denied the motion explaining that its ruling was based on Luminati’s representation that it had produced all relevant EMK documents in its possession. But the court added that Tesonet had leave to pursue discovery directly from EMK through the Hague Convention, in light of Tesonet’s representation that it would “not seek to change the trial date or any other deadline.”

On November 15, 2019, Tesonet moved the court to sign a Letter Rogatory. Tesonet stated that while Luminati opposed the motion based on a purported delay, the delay was caused by Tesonet’s need to retain U.K. counsel and to prepare a conforming Letter Rogatory. In response, Luminati argued first that Tesonet’s request was irreconcilable with its earlier statement to the court that it did not want a delay and would not ask for a delay on account of the overseas discovery request. Luminati then argued that Tesonet had not identified a specific need for EMK documents, nor had Tesonet explained how any documents could be admitted at trial when no EMK witnesses were identified on its trial witness list. Finally, Luminati argued that allowing the discovery would delay trial because a request to the U.K. would take between six and twelve months to complete, and that numerous pretrial deadlines had already passed, and Luminati would be highly prejudiced by any ensuing delay.

The court denied Tesonet’s motion and stated that it was “not convinced” that the trial date would hold if it allowed Tesonet to pursue the EMK discovery. The court also explained that it “seriously doubt[ed]” whether the discovery could be completed in time given that trial was two months away. Furthermore, the court found that Luminati would be prejudiced.

Luminati Networks Ltd. v. UAB Tesonet, 18-cv-00299, slip op. (E.D. Tex. Nov. 27, 2019) (Gilstrap, C.J.)

Practice Tip: Litigants contemplating discovery through the Hague Convention should prepare early in the discovery period and seek overseas counsel as early as possible to minimize delays in preparing suitable foreign discovery requests for the court’s approval.

Share This Insight

Previous Entries

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.